We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

206 hedge funds and large institutions have $1.62B invested in BioCryst Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $77.9M | Put options by funds: $38.7M

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

35% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 55

31% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 29

10% more capital invested

Capital invested by funds: $1.48B → $1.62B (+$141M)

8.26% more ownership

Funds ownership: 57.74% → 66.01% (+8.3%)

5% more funds holding

Funds holding: 197 → 206 (+9)

Holders
206
Holders Change
+9
Holders Change %
+4.57%
% of All Funds
3.17%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
38
Increased
74
Reduced
55
Closed
29
Calls
$77.9M
Puts
$38.7M
Net Calls
+$39.2M
Net Calls Change
+$1.69M

Top Buyers

1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$66.7M
2
RM
RP Management
New York
+$50.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$36.7M
4
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$25M
5
SI
Sofinnova Investments
California
+$20M

Top Sellers

1
HM
HealthCor Management
New York
-$19.5M
2
Two Sigma Investments
Two Sigma Investments
New York
-$13.8M
3
Federated Hermes
Federated Hermes
Pennsylvania
-$10.9M
4
Northern Trust
Northern Trust
Illinois
-$7.63M
5
Citadel Advisors
Citadel Advisors
Florida
-$7.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$15.7M +$2.11M +159,731 +16%
GIM
27
Granahan Investment Management
Massachusetts
$15.7M +$3.48M +262,658 +30%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$11.9M +$1.46M +110,111 +15%
Goldman Sachs
29
Goldman Sachs
New York
$11.3M +$608K +45,965 +6%
Norges Bank
30
Norges Bank
Norway
$9.94M -$1.05M -79,000 -10%
Voloridge Investment Management
31
Voloridge Investment Management
Florida
$9.61M -$6.44M -486,467 -41%
MB
32
MPM BioImpact
Massachusetts
$9.17M -$567K -42,816 -6%
Osaic Holdings
33
Osaic Holdings
Arizona
$7.76M +$675K +51,030 +10%
UBS Group
34
UBS Group
Switzerland
$7.38M +$2.57M +194,262 +57%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$6.27M +$3.28M +247,639 +121%
NSIM
36
North Star Investment Management
Illinois
$6.23M +$91.3K +6,900 +2%
Victory Capital Management
37
Victory Capital Management
Texas
$6.11M -$303K -22,908 -5%
PHP
38
Parkman Healthcare Partners
Connecticut
$5.54M +$3.94M +298,040 +292%
Citadel Advisors
39
Citadel Advisors
Florida
$5.52M -$7.38M -557,481 -58%
Swiss National Bank
40
Swiss National Bank
Switzerland
$5.44M – – –
Citigroup
41
Citigroup
New York
$5.39M +$3M +226,689 +140%
Morgan Stanley
42
Morgan Stanley
New York
$5.21M -$649K -49,008 -12%
Bank of America
43
Bank of America
North Carolina
$4.94M -$2.98M -224,960 -39%
GGHC
44
Gilder Gagnon Howe & Co
New York
$4.72M +$357K +26,973 +9%
PAM
45
Panagora Asset Management
Massachusetts
$4.54M +$1.38M +104,126 +47%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$4.34M +$33.2K +2,509 +0.8%
First Trust Advisors
47
First Trust Advisors
Illinois
$4.24M +$785K +59,305 +24%
BIA
48
Biondo Investment Advisors
Pennsylvania
$3.73M +$27.8K +2,100 +0.8%
SG Americas Securities
49
SG Americas Securities
New York
$3.69M -$902K -68,163 -20%
Allianz Asset Management
50
Allianz Asset Management
Germany
$3.64M +$1.58M +119,407 +83%
1
2
3 4 5

BCRX Hedge Fund Activity: Q4 2021 in Review

206 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2021, worth a combined $1.62B — up 9.5% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new BCRX positions and 29 closed out — a net gain of 9 holders — while 74 added to existing stakes and 55 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $66.7M. The largest seller was HealthCor Management, cutting an estimated $19.5M.

  • 206 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2021, up from 197 in Q3 2021.
  • Funds reported $1.62B of BioCryst Pharmaceuticals stock for Q4 2021, up 9.5% quarter-over-quarter.
  • 38 funds opened new BioCryst Pharmaceuticals positions in Q4 2021 and 29 closed out, a net change of +9 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $66.7M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2021 was HealthCor Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2021.